Biomaterial-based immunotherapeutic strategies for rheumatoid arthritis

• Published in: Drug delivery and translational research Vol. 11; no. 6; pp. 2371 - 2393
• Main Authors: Tu, Allen B., Lewis, Jamal S.
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.12.2021
• Subjects: Arthritis, Rheumatoid - drug therapy; Biocompatible Materials; Biomedical and Life Sciences; Biomedicine; Humans; Immunotherapy; Original; Original Article; Pharmaceutical Sciences/Technology; Autoimmunity; Drug delivery; Nanomedicine; Rheumatoid arthritis; Biomaterials
• ISSN: 2190-393X; 2190-3948
• DOI: 10.1007/s13346-021-01038-w

Rheumatoid arthritis (RA) is an extremely painful autoimmune disease characterized by chronic joint inflammation leading to the erosion of adjacent cartilage and bone. Rheumatoid arthritis pathology is primarily driven by inappropriate infiltration and activation of immune cells within the synovium of the joint. There is no cure for RA. As such, manifestation of symptoms entails lifelong management via various therapies that aim to generally dampen the immune system or impede the function of immune mediators. However, these treatment strategies lead to adverse effects such as toxicity, general immunosuppression, and increased risk of infection. In pursuit of safer and more efficacious therapies, many emerging biomaterial-based strategies are being developed to improve payload delivery, specific targeting, and dose efficacy, and to mitigate adverse reactions and toxicity. In this review, we highlight biomaterial-based approaches that are currently under investigation to circumvent the limitations of conventional RA treatments. Graphical abstract